New drug development for conquering ulcerative colitis drives competition among global pharmaceutical companies. Competition in the market will likely intensify due to the efficacy shown by new drugs, including JAK inhibitors Rinvoq and Xeljanz, anti-integrin drugs, and S1P receptor modulators, in clinical trials, in addition to biological medicine Omvoh, a recently approved drug. While TNF-alpha inhibitors such as Humira and Remicade currently dominate the market for ulcerative colitis, the market landscape is forecasted to change.

Omvoh, Eli Lily’s interleukin (IL)-23 inhibitor, has been approved in Korea, the industry said on the 27th. Omvoh can treat patients with ulcerative colitis who have previousl